Skip to main content

CORRECTION article

Front. Oncol., 27 September 2019
Sec. Pharmacology of Anti-Cancer Drugs
This article is part of the Research Topic Design and Application of Innovative Local Treatments in Glioblastoma and Other Cancers View all 12 articles

Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

Hanbo Cao Hanbo Cao 1Wenjun Li Wenjun Li 1Yizhou Zhou Yizhou Zhou 1Renxiang Tan Renxiang Tan 2Yue Yang Yue Yang 1You Zhou You Zhou 1Qinglong Guo Qinglong Guo 1Li Zhao Li Zhao 1
  • 1 State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, China
  • 2 State Key Laboratory Cultivation Base for TCM Quality and Efficacy, Nanjing University of Chinese Medicine, China

A Corrigendum on
Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway

by Cao, H., Li, W., Zhou, Y., Tan, R., Yang, Y., Zhou, Y., et al. (2019). Front. Oncol. 9:188. doi: 10.3389/fonc.2019.00188

In the original article, there was a mistake in Figure 3H as published. Due to carelessness, the picture of the “k562-indo group” was accidentally placed in the “ku812-indo group”. The corrected Figure 3H appears below.

FIGURE 3
www.frontiersin.org

Figure 3.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Keywords: bone marrow environment, CXCL12/CXCR4, oroxylin A, Imatinib (IM), β-catenin/P-gp

Citation: Cao H, Li W, Zhou Y, Tan R, Yang Y, Zhou Y, Guo Q and Zhao L (2019) Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway. Front. Oncol. 9:990. doi: 10.3389/fonc.2019.00990

Received: 09 September 2019; Accepted: 16 September 2019;
Published: 27 September 2019.

Edited and reviewed by: Carmen Alvarez-Lorenzo, University of Santiago de Compostela, Spain

Copyright © 2019 Cao, Li, Zhou, Tan, Yang, Zhou, Guo and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qinglong Guo, anticancer_drug@163.com; Li Zhao, zhaoli@cpu.edu.cn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.